CADL Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 16:00):
Our systems believe the stock currently is overvalued by 0.09% compare to its pairs and should correct downwards.

Stats
Today's Volume	999 743
Average Volume	5.53M
Market Cap	264.71M
EPS	$-0.290 ( 2023-11-09 )
Next earnings date	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.89
ATR14	$0.0330 (0.37%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-12	Schoch Charles	Sell	0	Common Stock
2024-01-12	Schoch Charles	Sell	0	Common Stock
2024-01-12	Schoch Charles	Sell	25 000	Stock Option (Right to Buy)
2024-01-12	Schoch Charles	Sell	39 498	Stock Option (Right to Buy)
2023-11-28	Tyagarajan Seshu	Sell	17 328	Common Stock

INSIDER POWER
76.72
Last 92 transactions
Buy: 8 106 969 \| Sell: 4 393 086

Correlation (AI algo v.1.1b): Overvalued: -0.09% $9.19 paired level. (The Algo Track The Changes Of The Most Correlated Stocks In Realtime And Give An Instant Update)

Volume Correlation

Long: 0.05 (neutral)

Short: 0.45 (neutral)

Signal:(33.833) Neutral

Candel Therapeutics, Inc. Correlation

10 Most Positive Correlations
SCTL	0.94
MESO	0.938
LABP	0.929
SMTC	0.925
MOTNU	0.923
NN	0.918
QRHC	0.916
PAYS	0.916
STOK	0.915
SRTS	0.913

10 Most Negative Correlations
ATHN	-0.936
PTRA	-0.923
ARIZ	-0.92
AEY	-0.902
LUCD	-0.895
ONEM	-0.89
EZGO	-0.89
LULU	-0.886
SFT	-0.881
AFYA	-0.878

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Candel Therapeutics, Inc. Correlation - Currency/Commodity

0.33
( neutral )

0.43
( neutral )

0.00
( neutral )

0.38
( neutral )

0.24
( neutral )

Candel Therapeutics, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-1.20M (0.00 %)
EPS:	$-1.310

FY	2023
Revenue:	$0
Gross Profit:	$-1.20M (0.00 %)
EPS:	$-1.310

FY	2022
Revenue:	$125 000
Gross Profit:	$-862 000 (-689.60 %)
EPS:	$-0.0994

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.934

Financial Reports:

No articles found.

Candel Therapeutics, Inc.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.

Realtime updates for Candel Therapeutics, Inc. [CADL]

Upcoming Earnings Alert